1Roger JP.Reservoirs of human immunodeficiency virus type 1:the main obstacles to viral eradication[J].Clinical Infectious Diseases,2002,34:91-97.
2Persaud D,Pierson T,Ruff C,et al.A stable latent reservoir for HIV-1 in resting CD4 T-lymphocytes in infected children[J].J Clin Invest,2000,105:995-1003.
3Brooks DG,Kitchen SG,Kitchen KMP,et al.Generation of HIV latency during thympoiesis[J].Nat Med,2001,7:459-464.
4Sonza S,Mutimer HP,Oelrichs R,et al.Monocytes harbour replication-compentent,non-latent HIV-1 in patients on highly active antiretroviral therapy[J].AIDS,2001,15:17-22.
5Gunthard,HF,Havlir,DV,Fiscus S,et al.Residual human immunodeficiency virus(HIV)type 1RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years[J].Infect Dis,2001,183:1318-1327.
6Pierson T,Hoffman TL,Blankson J,et al.Charaterization of chemokine receptor utilization of viruses in the latent reservoirs for human immunodeficiency virus type 1[J].J Virol,2000,74:7824-7833.
7Eron JJ Jr,Smeaton LM,Fiscus SA,et al.The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen[J].J Infect Dis,2000,181:1622-1628.
8Cu-Uvin S,Caliendo AM,Reinert S,et al.Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA[J].AIDS,2000,14:415-421.
9Huisman MT,Smit JW,Schinkel AH.Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors[J].AIDS,2000,14:237-242.
10Sharkey ME,Teo I,Greenough T,et al.Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy[J].Nat Med,2000,6:76-81.
